Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

The tide is turning in America’s COVID policy, with the recent announcement that the federal government will no longer recommend booster shots for most healthy Americans under the age of 65. This ...

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Vinay Prasad is leaving Sensible Medicine to take a senior role at the US FDA. He has our enthusiastic support. Prasad is ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the ...

The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

A strategy of selecting stocks based on rapid revenue growth has outperformed the broad market over the decades MarketWatch's Brett Arends covered research showing that a combination of looking back ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...